EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary ...
If approved, tabelecleucel will be the first FDA-authorized treatment for relapsed/refractory EBV+ PTLD patients whose ...
Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced research advancing understanding of Prader-Willi syndrome and ...
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its ...
Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with ...
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no ...
Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software.
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a new installment of its CEO ...
Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the ...
September 29, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, ...
Today, separately announcing a proposed capital raise to further strengthen the balance sheet Cash and short-term deposit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results